The Use of Immunotherapy In RCC: Where are we Now?
March 16, 2023
March 16, 2024
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by The France Foundation and the Kidney Cancer Association.
This activity is supported by a grant from Merck.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
The target audiences for this education are urologists, oncologists, PAs, nurse practitioners, and other health care professionals involved in the management of patients with RCC.
Learn the latest clinical information related to the treatment of renal cell carcinoma (RCC) with immune checkpoint inhibitors with three experts through case studies.
Upon completion of this activity, participants should be better able to:
- Review immunotherapies and therapy combinations for the management of both malignant RCC and adjuvant treatment
- Select an appropriate immunotherapeutic agent for patients with RCC based on individual patient characteristics and needs
- Monitor RCC patients receiving immunotherapy for adverse events
- Manage adverse events in a timely fashion in RCC patients receiving immunotherapy
Pedro Barata, MD, MSc
Associate Professor of Medicine
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Tian Zhang, MD, MHS
Department of Internal Medicine
UT Southwestern Medical Center
Kiran Virdee, BSN, RN
Memorial Sloan Kettering Cancer Center
New York, New York
In support of improving patient care, this activity has been planned and implemented by The France Foundation and the Kidney Cancer Association. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
|Name of Individual||Role in Activity||Name of Commercial Interest(s)||Nature of Relationship(s)||Mechanism(s) implemented to resolve conflict of interest|
|Amanda Noe||TFF Staff||No relevant financial disclosures||n/a||n/a|
|Kiran Virdee, BSN, RN||Planning Committee, Faculty||No relevant financial disclosures||n/a||n/a|
|Kristen Brady||TFF Staff||No relevant financial disclosures||n/a||n/a|
|Margaret Das, PhD||Planning Committee, TFF Medical Reviewer||No relevant financial disclosures||n/a||n/a|
|Patrick Harty, PhD||TFF Medical Reviewer||No relevant financial disclosures||n/a||n/a|
|Pedro Barata, MD, MSc||Planning Committee, Faculty||
||All final planning
content, learning objectives,
and evaluation questions were
made by the non-conflicted
Planning Committee Chair
Content was reviewed by a
non-conflicted member of the
planning committee to ensure
that it is not commercially
biased, was fair-balanced, and
is based on scientific evidence
and/or clinical reasoning
|Tian Zhang, MD, MHS||Planning Committee, Faculty||
||The following relationships with
commercial entities have mitigated
by the relationship ending:
All final planning decisions concerning
content, learning objectives, and evaluation
questions were made by the non-conflicted
Planning Committee Chair Content was
reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for download after completion.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
The France Foundation and Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Kidney Cancer Association, and the commercial supporter(s) assume no liability for the information herein.
For CME questions please contact: [email protected].